Vortioxetine: first global approval.

Item

http://www.wikidata.org/entity/Q48390325

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Vortioxetine: first global approval.

@en

Vortioxetine: first global approval.

@nl

type

Item

label

Vortioxetine: first global approval.

@en

Vortioxetine: first global approval.

@nl

prefLabel

Vortioxetine: first global approval.

@en

Vortioxetine: first global approval.

@nl

P1476

Vortioxetine: first global approval.

@en

P2093

Andrew Gibb

http://www.w3.org/2001/XMLSchema#string

Emma D Deeks

http://www.w3.org/2001/XMLSchema#string

P2860

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder.

Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.

A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.

Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States.

A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.

A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.

Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.

Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats.

P2888

s40265-013-0161-9

P304

135-145

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-013-0161-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24311349

http://www.w3.org/2001/XMLSchema#string